Organisation paid for research Program year 2025 Source: CMS Open Payments

Iact Health

Neither a doctor nor a teaching hospital

Research payments

$8,754,501

3,166 payments

Through program year 2025, Iact Health is reported as receiving $8,754,501 in research payments, across 3,166 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,364 4
2024 Research $669,238 124
2023 Research $2,290,807 1,338
2022 Research $1,456,450 984
2021 Research $3,146,967 406
2020 Research $1,098,757 294
2019 Research $88,918 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $3,510,095 2,064 payments
  2. Regeneron Pharmaceuticals, Inc. $2,036,578 393 payments
  3. Merck Sharp & Dohme Corporation $1,038,800 39 payments
  4. Eli Lilly and Company $919,372 20 payments
  5. Novartis Pharmaceuticals Corporation $388,439 2 payments
  6. Incyte Corporation $365,074 77 payments
  7. AstraZeneca Pharmaceuticals LP $240,620 38 payments
  8. Novo Nordisk AS $123,548 464 payments
  9. Celgene Corporation $30,881 8 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $26,632 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,318,919 96 payments
  2. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $1,240,091 163 payments
  3. A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. $866,667 8 payments
  4. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $697,255 6 payments
  5. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $503,472 182 payments
  6. Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults $449,585 555 payments
  7. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $418,863 27 payments
  8. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $390,325 333 payments
  9. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 (The Empathy Trial) $305,712 1 payment
  10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $288,031 43 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record